Oral versus intravenous maternal hydration in isolated third trimester oligohydramnios

Humaira Zafar1*, Mubahra Naz1, Umber Fatima1, Uzma Shahzad2, Anees Fatima1, Attiya Yasmin1

1Department of Obstetrics and Gynaecology, University Medical and Dental College, 2Department of Obstetrics and Gynaecology, Independent Medical College, Faisalabad, Pakistan

Received: 23 July 2020
Accepted: 20 August 2020

*Correspondence:
Dr. Humaira Zafar,
E-mail: humairazafar75@gmail.com

ABSTRACT

Background: To study the effect of oral and intravenous maternal hydration in patients with isolated oligohydramnios in terms of mean change in amniotic fluid.

Methods: A total number of 38 patients included in the study which fulfill the selection criteria. Patients were randomly divided in two groups. Amniotic fluid index (AFI) of all patients was measured before the hydration therapy according to the method of Phelan et al. In maternal oral hydration (Group A), every patient was instructed to drink two liters of water over two hours daily for 1 week. In intravenous hydration (Group B), every woman infused two liters of 0.9% normal saline in two hour daily for 1 week. After 48 hours and 1 week of oral and intravenous hydration, the AFI was reassessed by the same observer. Patients were monitored closely for sign and symptoms of fluid overload. Data was stratified for mean difference in improvement in amniotic fluid index.

Results: After oral hydration therapy AFI was 5.926±0.4593 after 48 hours and 8.286±0.6000 after 7 days in Group A. In Group B AFI was 5.784±0.4622 after 48 hours and 7.868±0.2810 after 7 days of intravenous hydration. P value after 48 hours is 0.348 and p=0.014 after 7 days means oral hydration therapy significantly increase amniotic fluid index.

Conclusions: Oral maternal hydration significantly increase the amniotic fluid index in patients with isolated oligohydramnios. It is simple, safe and non-invasive method.

Keywords: Amniotic fluid index, Intravenous hydration, Isolated oligohydramnios, Oral hydration

INTRODUCTION

An adequate amniotic fluid volume is necessary for intrauterine growth and fetal well-being. Oligohydramnios is defined as decreased amniotic fluid volume measured on ultrasound criteria which include AFI<5cm. Oligohydramnios complicates 8.5% to 15.5% of pregnancies.1

There are multiple causes of oligohydramnios like rupture membranes, hypertension, fetal urinary tract abnormalities, drugs or can be identified without any cause described above when it is called isolated oligohydramnios.2 Oligohydramnios is also observed in post term pregnancies and occurs in 12% pregnancies after 41 weeks of gestation.3
Oligohydramnios is invariably associated with increased rate of perinatal morbidity and mortality as a result of cord compression, fetal distress, pulmonary hypoplasia. Several treatment options have been suggested to improve the AFI like serial trans abdominal amino infusion, intra amniotic sealing techniques, Desmopressin use and fetal cystoscopy but all these modalities are costly, need hospitalization and associated with serious side effects. So maternal hydration is considered an effective and cheap intervention to treat oligohydramnios in resource poor setting like ours.

Maternal hydration increases the amniotic fluid through reduction in maternal plasma osmolality which result in increased AFI. The mother’s fluid balance has great impact on amniotic fluid. Increased maternal fluid intake leads to increase in AFI with oligohydramnios.

METHODS

The study was conducted in the department of Obstetrics and Gynecology Madina Teaching Hospital affiliated with University Medical and Dental College Faisalabad between July 2019 to December 2019.

Sample selection

Inclusion criteria

Inclusion criteria for the sample selection was AFI of <5 cm, 28-36 weeks of gestation, Intact membranes, Singleton pregnancy

Exclusion criteria

Exclusion criteria for the sample selection was maternal conditions (pre-eclampsia, cardiac disease, renal impairment, severe anemia), ruptured membranes, multiple pregnancy, congenital anomaly in fetus.

After taking approval from ethical committee, patients presenting in department of Obstetrics and Gynecology (OPD and indoor) which fulfill the inclusion and exclusion criteria were included in the study. Patients were equally distributed in two groups and remain admitted for the period of 1 week.

AFI of all patients was measured before the hydration therapy according to the method of Phelan et al which add the maximum vertical fluid pocket (devoid of cord and fetal parts) measured in 4 uterine quadrants.

In maternal oral hydration (Group A), every patient was instructed to drink two liters of water over two hours daily for 1 week. In intravenous hydration (Group B), every woman infused two liters of 0.9% normal saline in two hour daily for 1 week. After 48 hours and 1 week of oral and intravenous hydration, the AFI was reassessed by the same observer. Patients were monitored closely for sign and symptoms of fluid overload.

Data was stratified for mean difference in improvement in amniotic fluid index

The data was entered in statistical package for social science (SPSS V-16) software program and analyzed.

RESULTS

A total number of 38 patients were enrolled in this study. Sampled population was randomly divided in two groups. Each group contain 19 patients.

In all the patients included in the study, there was no vomiting and oral hydration well tolerated.

Age distribution shows that 68.42% (n=13) in group A and 57.89% (n=11) in Group B were between 18-30 years of age whereas 31.57% (n=6) in Group A and 42.10% (n=8) in Group B were between 31-38 years of age, mean±SD was calculated as 26.68±5.963 years in Group A and 28.79±5.760 years in Group B (Table 1).

Table 1: Age distribution (n=19).

<table>
<thead>
<tr>
<th>Age (in years)</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>%</td>
<td>No. of patients</td>
</tr>
<tr>
<td>18-30 Years</td>
<td>13</td>
<td>68.42%</td>
</tr>
<tr>
<td>31-38 Years</td>
<td>06</td>
<td>31.57%</td>
</tr>
<tr>
<td>Total</td>
<td>19</td>
<td>100%</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>26.68±5.963</td>
<td>28.79±5.760</td>
</tr>
</tbody>
</table>

Table 2: Gestational Age.

<table>
<thead>
<tr>
<th>Gestational age (in weeks)</th>
<th>Group A (n=19)</th>
<th>Group B (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>%</td>
<td>No. of patients</td>
</tr>
<tr>
<td>28-32 weeks</td>
<td>07</td>
<td>36.84%</td>
</tr>
<tr>
<td>32-36 weeks</td>
<td>12</td>
<td>63.15%</td>
</tr>
<tr>
<td>Total</td>
<td>19</td>
<td>100%</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>33.79±2.692</td>
<td>32.37±2.813</td>
</tr>
</tbody>
</table>

Regarding gestational age 36.84% (n=7) patients in Group A and 47% (n=9) in Group B were between 28-32 weeks of gestation whereas 63.15% (n=12) in Group A and 52.63% (n=10) in Group B were between 32-36 weeks of gestation. Mean age was 33.79±2.692 weeks in Group A and 32.37±2.813 weeks in Group B (Table 2).
Baseline mean AFI was 3.316±0.8368 in Group A before treatment and 3.211±0.8178 in Group B (p=0.697). After oral hydration therapy AFI was 5.926±0.4593 after 48 hours and 8.268±0.6000 after 7 days in Group A.

**Table 3: Comparison of increase in mean AFI volume.**

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Mean AFI</th>
<th>SD</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFI at baseline</td>
<td></td>
<td>Oral 19</td>
<td>3.316</td>
<td>0.8368</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>19</td>
<td>3.211</td>
<td>0.8178</td>
</tr>
<tr>
<td>AFI after 48 h</td>
<td></td>
<td>Oral 19</td>
<td>5.926</td>
<td>0.4593</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>19</td>
<td>5.784</td>
<td>0.4622</td>
</tr>
<tr>
<td>AFI after 7 days</td>
<td></td>
<td>Oral 19</td>
<td>8.268</td>
<td>0.6000</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>19</td>
<td>7.868</td>
<td>0.2810</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Amniotic fluid volume is a parameter that has significant role in evaluation of fetal wellbeing. It plays a major role in the development of fetus and allows development of musculoskeletal system. Adequate amniotic fluid is considered to be vital for fetus. This study was conducted to determine the role of hydration therapy in isolated oligohydramnios and the results shows that oral hydration is more effective in increasing amniotic fluid index as compare to intravenous hydration.

In our study we concluded that there is significant increase in mean AFI volume after oral hydration. The results were comparable to a study conducted in Faisalabad Medical University, Faisalabad.

Our findings were also agreed with study conducted in Egypt, they show the good effect of oral hydration over IV hydration.

Gizzo et al observed that in isolated oligohydramnios maternal oral hydration is more effective than intravenous hydration.

Although oral hydration is simple, inexpensive and non-invasive method but the compliance of the patient is very important factor. If well tolerated, will increase amniotic fluid volume and improve perinatal outcome.

Momina et al conducted a study on 226 women and found that oral hydration is better as compare to intravenous maternal hydration. The observations in our study were also supported by a randomized controlled trial that was conducted at institute of child and mother health, Dhaka.

The results of our study are also comparable to another study conducted by AC Rossi in 2013.

Kiran et al reported that both i.e. oral and intravenous hydration are effective in term of increase in amniotic fluid index.

Oligohydramnios is one of the prevalent threatening condition to fetal health. It is commonly associated with intrauterine growth restriction, fetal distress increased operative delivery and meconium aspiration. Oral hydration therapy is safe and inexpensive treatment and should be offered to the women with isolated third trimester oligohydramnios.

**CONCLUSION**

Oral maternal hydration significantly increases the amniotic fluid index in patients with isolated oligohydramnios. It can be used instead of intravenous hydration because it is simple, safe and noninvasive method. It is also easily acceptable to the patients.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**


